Showing 141 - 160 results of 64,995 for search '(( 50 ms decrease ) OR ( 5 ((((non decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 0.93s Refine Results
  1. 141
  2. 142

    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

    Published 2021
    “…Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151
  12. 152

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160